SI · CIK 1699350
What Shoulder Innovations, Inc. told the SEC could break it.
Shoulder Innovations' sharpest exposure is supply-chain fragility: the majority of its products come from single-source suppliers with no long-term contracts, and it relies on one supplier for the significant majority of sterilization — including a single supplier to sterilize all of its polyethylene implants — where replacing a vendor could take 6–12 months. That sits against financing pressure, with its Trinity loan collateralized by substantially all assets including IP and a $15M tranche conditioned on reaching $45M annualized revenue by December 2026. Selling the implants also depends on regulatory clearance — FDA approval and EU MDR notified-body requirements abroad — while tariffs on metals and metal powders imported from Canada and Europe could raise its material costs.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA medical-device clearance and EU MDR / UK notified-body recognitionmedium
Shoulder Innovations' implant systems require FDA clearance and hospital/ASC approval, and any international expansion faces EU MDR notified-body requirements (with no UK–EU mutual recognition post-Brexit) — regulatory hurdles to selling its products.
“If hospitals, ASCs, and other health care facilities do not approve the use of our implant systems, our sales may not increase.”
SEC filing →As of 2026 - tariffs on imported metals (Canada/Europe metal powders for coatings)low
Certain of Shoulder Innovations' suppliers import raw materials (including metals and metal powders used for coating products) from Canada and Europe; threatened tariff increases on those imports could significantly raise material/component costs.
“there have been and continue to be further indications that there may be an increase in tariff rates on various types of goods imported from Canada and Europe that could apply to the raw materials we require in our products, including certain types of metal powders used for coating our products.”
SEC filing →As of 2026
Sole-source dependency
- majority of products from single-source suppliers; single sterilization supplier for polyethylene implantshigh
The majority of Shoulder Innovations' products come from single-source suppliers (Avalign, Micropulse, Trifecta, Revelation) with no long-term contracts; it also uses one supplier for the significant majority of sterilization (and a single supplier to sterilize all polyethylene implants), and replacing a supplier could take 6–12 months with no assured second source.
“The majority of our products are provided by single-source suppliers.”
SEC filing →As of 2026
Liquidity & debt
- Trinity Loan Agreement secured by substantially all assets (incl. IP), with covenants and revenue-milestone tranchesmedium
Shoulder Innovations' Trinity Loan is collateralized by substantially all assets including IP, with covenants limiting asset sales, change of control, mergers and affiliate transactions; a $15M tranche availability is conditioned on hitting $45M annualized revenue by Dec 2026.
“Our obligations under the Trinity Loan Agreement are collateralized by substantially all of our assets, including intellectual property, and we are subject to customary affirmative and negative covenants limiting our ability to, among other things, relocate or dispose of assets, undergo a change in control, merge or consolidate, enter into certain transactions with aff”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Trifecta Medical Group
“Our significant single source suppliers include Avalign Technologies, Inc., which manufactures our humeral stems, Micropulse, Inc., which manufactures and supplies our InSet Glenoid products, Trifecta Medical Group, which manufactures our instrument cases and trays and Revelation Medical Devices, which manufactures the surgical instruments used during procedures involving our systems.”
Cited →Genesis Software
“We are also required to pay Genesis Software royalties of a mid-single-digit percentage on net sales of shoulder replacement products that incorporate or use the Licensed Software until the earlier of (i) the tenth anniversary of the effective date of the License Agreement”
Cited →Avalign Technologies, Inc.
“Our significant single source suppliers include Avalign Technologies, Inc., which manufactures our humeral stems, Micropulse, Inc., which manufactures and supplies our InSet Glenoid products, Trifecta Medical Group, which manufactures our instrument cases and trays and Revelation Medical Devices, which manufactures the surgical instruments used during procedures involving our systems.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch